NDAINJECTIONINJECTABLE
Approved
Jan 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
MAXIPIME (cefepime hydrochloride) by Pfizer is [ see microbiology ( ]. Approved for the treatment of pneumonia (moderate to severe) caused by susceptible strains of streptococcus pneumoniae, including cases associated with concurrent bacteremia, pseudomonas aeruginosa and 15 more indications. First approved in 1996.
Drug data last refreshed 55m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAXIPIME (cefepime hydrochloride) is a fourth-generation cephalosporin antibiotic administered by injection for moderate-to-severe bacterial infections. It treats pneumonia, urinary tract infections, skin/soft tissue infections, and intra-abdominal infections caused by susceptible gram-positive and gram-negative organisms. The drug works by inhibiting bacterial cell wall synthesis through beta-lactam mechanism of action.
LOE Approaching
Drug is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling transition from growth to decline phase requiring strategic repositioning and potential team reductions.
Mechanism of Action
[ See Microbiology ( ].
Worked on MAXIPIME at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.